Physician profile
Sean R Tunis
$361,450.17
in general payments reported to CMS, 2019-2025
14 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $51K · 2021: $34K · 2022: $36K · 2023: $102K · 2024: $32K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $158K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,032 · Honoraria: $7,200 · Travel and Lodging: $3,245 · Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $157,679.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,031.69 |
| Honoraria | $7,200.00 |
| Travel and Lodging | $3,244.91 |
| Food and Beverage | $219.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67,141.72 | 2019-2023 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $67,058.08 | 2019-2023 | Zolgensma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37,489.15 | 2023-2024 | Jardiance |
| Edwards Lifesciences Corporation | $34,449.22 | 2023-2025 | |
| Ucb Sa | $27,654.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $27,300.00 | 2023-2025 | Invega Sustenna |
| Astrazeneca Uk Limited | $27,000.00 | 2024-2025 | Tagrisso |
| Otsuka America Pharmaceutical, INC. | $21,350.00 | 2020-2023 | |
| Amgen INC. | $15,058.00 | 2019 | |
| Allergan, INC. | $11,200.00 | 2019 | |
| Biogen, INC. | $9,900.00 | 2020 | |
| Eisai INC. | $7,200.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,850.00 | 2020 | |
| Neurocrine Biosciences, INC. | $2,800.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Tunis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.